Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Bevacizumab + Dostarlimab-gxly + GSK5733584 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Bevacizumab | Avastin | VEGF Antibody 15 VEGFR Inhibitor (Pan) 36 | Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov). | |
| Dostarlimab-gxly | Jemperli | Dostarlimab|TSR-042 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | Jemperli (dostarlimab-gxly) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 34313545). Jemperli (dostarlimab-gxly) is FDA approved for use in patients with recurrent or advanced endometrial cancer or solid tumors harboring mismatch repair deficient (dMMR), as determined by an FDA-approved test, who have progressed on prior treatments, and in combination with Paraplatin (carboplatin) and Taxol (paclitaxel), followed by Jemperli (dostarlimab-gxly) monotherapy, in patients with primary advanced or recurrent endometrial cancer (FDA.gov). |
| GSK5733584 | GSK 5733584|GSK-5733584|HS-20089 | GSK5733584 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting VTCN1 (B7-H4) linked to a topoisomerase I inhibitor, which potentially induces apoptosis in VTCN1 (B7-H4)-expressing tumor cells (Cancer Res (2025) 85 (8_Supplement_2): CT188, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|